Latest offering leverages automation in the payment process for travel, childcare, and more.
Medidata has announced the launch of its newest solution, Patient Payments. Headlined by the use of automation, this offering aims to streamline trial-related stipends and reimbursements for patients.1
Medidata Patient Payments will deliver an experience centered around making the lives of patients easier. Participants in clinical research have the capability of quickly submitting request for various types of payments including travel, meals, lodging, lost wages, childcare, and mileage. This latest offering leverages the Medidata Platform, which will automatically trigger stipends by the completion of study activities like diaries or assessments. Patient Payments will be accessible via myMedidata.
According to Medidata, the Medidata Platform offers stakeholders a single solution to manage their trials. It connects patients, sites, sponsors, and CROs in a cloud environment. The myMedidata solution is a patient portal built by patients, providing a single destination for trial engagement and education.
“Our Patient Payments solution is a direct reflection of the commitment and passion we have to deliver an extraordinary patient experience,” Meghan Harrington, vice president, Clinical Trial Financial Management, Medidata said in a press release. “Our partnerships with Medidata’s patient and site advisory boards, coupled with the incomparable data housed within our ecosystem, provides us with a unique opportunity to modernize the financial management experience for patients.”
Earlier in June, Medidata announced the launch of Medidata Clinical Data Studio, a data management solution. Also built on the Medidata Platform, Clinical Data Studio leverages data from both Medidata and outside sources. With the introduction of artificial intelligence (AI), study teams can more effectively identify challenges during a study.2
In an earlier press release, Tom Doyle, chief technology officer, Medidata said, “Clinical Data Studio unlocks the broad ecosystem of clinical data. Powered by embedded AI, we are democratizing access to data and revealing the signals, risks, and insights that matter most. Together this accelerates trial execution and creates rich data for new discoveries.”
Clinical Data Studio also includes data reconciliation and anomaly detection, self-serve data listings, risk-based quality management, and more powered by AI.
Nimita Limaye, PhD, research vice president, life sciences R&D strategy and technology, IDC added, “As data volume and sources grow exponentially, managing this data and garnering real-time insights is becoming increasingly complex. Not only is this impacting time-to-market, but it is also delaying the timely delivery of therapies to patients, thus impacting patients' lives. By enabling users to manage all their data, both Medidata and non-Medidata data, in one place, Medidata Clinical Data Studio has the potential to disrupt the industry by accelerating clinical trials and getting therapies to patients faster.”
1. Medidata Extends Its Commitment to the Patient Experience with the Launch of Patient Payments. News release. Medidata. September 25, 2024. Accessed September 26, 2024. https://www.medidata.com/en/about-us/news-and-press/medidata-extends-its-commitment-to-the-patient-experience-with-the-launch-of-patient-payments/
2. Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials. News release. Medidata. June 18, 2024. Accessed September 26, 2024. https://www.medidata.com/en/about-us/news-and-press/medidata-launches-clinical-data-studio-leveraging-ai-to-modernize-the-data-experience-in-clinical-trials/
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.